"One important element of this effort will be to ensure that we are properly informed going forward about the cyberthreats posed by criminals, terrorists and hostile nations," says Sen. Sheldon Whitehouse, sponsor of the Cybersecurity Public Awareness Act.
While the cause of the Epsilon e-mail breach has not been publicly disclosed, the incident's aftermath has seen a growing list of organizations impacted by the breach. It also has ignited a new debate about the sensitivity of e-mail addresses.
Verizon's newly-released 2011 Data Breach Investigations Report finds that the number of compromised records has dropped dramatically, but incidents are up, and hackers are still finding new ways to get into systems and servers.
Privacy advocates in Maine are supporting a proposed state law that would require patients opt in to participate in the state's health information exchange before clinicians can access their records via the HIE.
The latest Verizon Data Breach Investigations Report is out, and the good news is: The number of compromised records is down. The troubling news is: The number of breaches is up. Bryan Sartin, one of the report authors, explains why.
As details about the Epsilon e-mail breach unfold, the list of affected companies grows, including major banks and merchants. Here is the latest list of the companies known to have been impacted by the incident.
The Social Security Administration sold the information in a database of deceased individuals that erroneous contained the Social Security numbers, dates of birth, full names and ZIP codes of living people, the inspector general reports.
The HITECH Act electronic health record incentive program marked a landmark April 18. Hospitals and physicians can now use an attestation system to begin verifying to Medicare that they qualify as meaningful users of certified electronic health records
Participants in a new pilot project claim they've demonstrated that using interoperable digital identities, digital signatures and cloud computing has the potential to accelerate the initiation of clinical trials of new drugs and treatments while lowering costs.